1. Home
  2. PDSB vs XLO Comparison

PDSB vs XLO Comparison

Compare PDSB & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$0.96

Market Cap

49.5M

Sector

Health Care

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.64

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDSB
XLO
Founded
2005
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.5M
41.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PDSB
XLO
Price
$0.96
$0.64
Analyst Decision
Strong Buy
Buy
Analyst Count
2
1
Target Price
$9.00
$2.00
AVG Volume (30 Days)
686.2K
305.9K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$31,804,000.00
Revenue This Year
N/A
$626.78
Revenue Next Year
N/A
$79.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
588.40
52 Week Low
$0.70
$0.62
52 Week High
$2.20
$1.70

Technical Indicators

Market Signals
Indicator
PDSB
XLO
Relative Strength Index (RSI) 54.58 39.17
Support Level $0.92 $0.63
Resistance Level $1.02 $0.74
Average True Range (ATR) 0.09 0.03
MACD 0.01 -0.00
Stochastic Oscillator 51.06 10.01

Price Performance

Historical Comparison
PDSB
XLO

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: